Skip to content
CompoundSci
All peptides
Research vial labelled GLP-1 analogs, a Incretin / GLP-1 class peptide studied in preclinical and clinical literature

GLP-1 analogs

Semaglutide class

Large phase 3 programmes across type 2 diabetes and obesity, plus cardiovascular outcome data.

The largest randomised evidence base of anything on this list.

General profile

Class
Incretin / GLP-1 class
Evidence
Strong human evidence
Studied dose range
0.25 mg titrating upward
Frequency in protocols
Weekly
Route
Subcutaneous
Half life
~5 days
Reconstitution
Per manufacturer labelling
Storage
Refrigerated

Timing and cycling in the literature

Usually dosed in the morning window

Once weekly, same day each week

Roughly five-day half-life, so the specific hour is irrelevant. What matters is holding the same weekday and titrating slowly, since fast escalation drives the nausea and vomiting seen in trials.

Reported cycle: 68 weeks on, run continuously in trials

This class is studied as continuous therapy with a slow titration, not as a cycle. The 68 week trial length is the reference point.

Watch for: Nausea and vomiting during escalation, dehydration, gallbladder pain, muscle loss without protein and resistance training, and any personal or family history of medullary thyroid cancer.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Hard stopTiming

    GLP-1 analogs + Tirzepatide

    Never run two incretin agonists together

    Both act on the GLP-1 receptor. Stacking them does not add benefit, it stacks the same gastric emptying delay and the same nausea, dehydration and gallbladder risk. Trials study one at a time for exactly this reason.

  • Hard stopTiming

    GLP-1 analogs + Retatrutide

    Never run two incretin agonists together

    Overlapping GLP-1 signalling with an added glucagon arm. The combined gastrointestinal and heart rate effects are additive and untitratable.

  • Separate syringesSame day fine, same syringe not

    GLP-1 analogs + Anything else, including another incretin

    Solo in the barrel, always

    Every incretin gets its own syringe and its own draw, including alongside another incretin. Protocol stacking is a real thing and is not a hard stop, but co-drawing is never part of it.

  • Separate syringesTiming

    GLP-1 analogs + AOD-9604

    Separate by at least a day

    Overlapping metabolic and appetite effects with heavily overlapping gastrointestinal side effects. Running them together makes it impossible to attribute nausea to either compound, which is exactly what you need to be able to do when titrating.

  • Separate syringesTiming

    GLP-1 analogs + Tesamorelin

    Do not start in the same week

    GLP-1 agonists slow gastric emptying and change glucose handling, while growth-hormone axis compounds push glucose the other way. Introducing both at once makes glycaemic changes unreadable and, in the trial literature, is where the insulin-resistance signal shows up.

  • Pick oneSame day fine, same syringe not

    GLP-1 analogs + Another incretin in a designed protocol

    Stacking is a protocol decision, not redundancy

    Multi-incretin work uses different receptor balances, so it is not the same button pressed twice. It only makes sense with the job named first, each dose lowered against solo use, titration on response, protein defence and side effect monitoring. Insulin or sulfonylureas are physician territory.

  • Pick oneTiming

    GLP-1 analogs + Cagrilintide

    Studied together, still introduce one at a time

    The amylin plus GLP-1 combination is the actual subject of the CagriSema trials, so the pairing is documented. What is not documented is starting both in the same week: appetite suppression and nausea compound, and you cannot tell which one to slow down.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how GLP-1 analogs fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: Tens of thousands of participants in registrational trials.

Open questions: Muscle loss, weight regain after discontinuation and long-horizon use in non-obese people remain open questions.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature